Glucocorticoids and Lipocortin
The steroids are the most useful anti-inflammatory drugs that we possess, effective against virtually any type of inflammation. The naturally occurring hormone hydrocortisone is still used in clinical medicine, but in many cases it has been superseded by synthetic analogues which have vastly increased duration of action and potency, making them particularly valuable to the dermatologist. As a group, the steroidal anti-inflammatories are amongst the most widely prescribed drugs in the world.
KeywordsSystemic Lupus Erythematosus Glucocorticoid Receptor Arachidonic Acid Release Prostaglandin Biosynthesis Eicosanoid Synthesis
Unable to display preview. Download preview PDF.
- Cirino G, Flower RJ (1987 b) The inhibitory effect of lipocortin on eicosanoid synthesis is dependent on divalent cation. Br J Pharmacol 92:521PGoogle Scholar
- Cirino G, Peers SH, Flower RJ, Browning J, Pepinsky RB (1989) Human recombinant lipocortin I has acute local anti-inflammatory properties in the rat paw oedema test. Proc Natl Acad Sci USA (in press)Google Scholar
- Flower RJ (1984) Macrocortin and the antiphospholipase proteins. In: Weissman G (ed) Advances in inflammation research, vol 8. Raven, New York, p 1Google Scholar
- Flower RJ, Wood JN, Parente L (1984) Macrocortin and the mechanism of action of the glucocorticoids. In: Otterness I, Capetola R, Wong S (eds) Advances inflammation research, vol 7. Raven, New York, p 61Google Scholar
- Flower RJ, Moon-Parvin D, Peers SH, Pepinsky RB, Taylor RD (1986) A novel assay for assessing the binding of phospholipase A2 to substrate. Br J Pharmacol 89:743PGoogle Scholar
- Herbaczynska-Cedro K, Staszewska-Barczak J (1974) Adrenocortical hormones and the release of prostaglandin-like substances (PLS) (Abstr). 2nd Congress of the Hungarian Pharmacological Society, BudapestGoogle Scholar
- Hirata F, Delcarmine R, Nelsom CA, Axelrod J, Schiffmann E, Warabi A, Deblas AL et al. (1981) Presence of autoantibody for phospholipase inhibitory protein(s) by radioim-muno-assay for lipomodulin. Biochem Biophys Res Commun 78:3190–3194Google Scholar
- Ilchyshyn A, Ilderton E, Kingsbury JA, Yardley HJ (1984) Evidence that the raised level of phospholipase A2 in the uninvolved epidermis of psoriasis is caused by hyperphos-phorylation of an inhibitor. Br J Dermatol 111:721–722Google Scholar
- Ilchyshyn A, Ilderton E, Pepinsky B, Yardley HJ (1986) Inhibition of phospholipase A2 activity in extracts of psoriatic epidermis by lipocortin. 4th International Symposium on Psoriasis, Stanford, USAGoogle Scholar
- Okamoto M, Tojo H, Ono T, Yamano T (1985 b) Comparative study of intracellular and pancreatic phospholipase A2. Adv Prostaglandin Thromboxane Leukotriene Res 15:135Google Scholar
- Podgorski MR, Goulding NJ, Hall ND, Flower RJ, Maddison PJ, Pepinsky RB (1987) Autoantibodies to recombinant lipocortin in RA and SLE. Br J Rheumatol [Suppl l]26:54–55Google Scholar
- Volwerk JJ, de Haas GH (1982) Pancreatic phospholipase A2: a model for membrane-bound enzymes? In: Jost PC, Griffiths OH (eds) Lipid-protein interactions, vol 1. Wiley, New York, pp 69–149Google Scholar